{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.402","upperLimit":"0.747","value":"0.575"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"To study the effect of adding bevacizumab to chemotherapy comprised of cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) on the event-free survival (EFS) in patients with localized resectable osteosarcoma. The Kaplan-Meier (K-M) method was used to estimate survival rate.","dispersionType":"95% Confidence Interval","groups":[{"description":"OS2008 Stratum A participants had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis.","id":"OG000","title":"A: Localized Resectable Disease"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"After all patients have completed therapy, up to 4 years after last patient is enrolled","title":"3-Year Event Free Survival","type":"PRIMARY","unitOfMeasure":"Probability"}